The efficacy of the addition of pembrolizumab to concurrent chemoradiation regimen using the best response achieved, as assessed by cystoscopy at weeks 19 and 31 of the trial (12 and 24 weeks post completion of chemoradiotherapy). Week 19 (12 weeks post chemotherapy) and Week 31 (24 weeks post chemotherapy) where cystoscopic examinations take place.
The number of patients to develop metastatic disease (i.e. the rate of metastatic disease), as assessed by CT scan (Through study completion, an average of 7 years).
The number of patients having a salvage cystectomy (i.e. the rate of salvage cystectomy), as assessed by cystoscopy (Through study completion, an average of 7 years).